« Return to News | R&D Trends | Drug Sponsors

Warner to cut 500 jobs

Monday, April 18, 2011 01:28 PM

After losing patent protection on their osteoporosis drug Actonel, Ireland-based Warner Chilcott is restructuring its E.U. operations and plans to cut 500 jobs in the process, according to Fierce Pharma. Actonel brought in about 70% of Warner's sales in Western Europe in 2010, and the drug is up against generic competition.

Warner will restructure its business in Belgium, the Netherlands, France, Germany, Italy, Spain, Switzerland and the U.K.  However, commercial operations in the U.K. and Germany will not be affected, nor will its headquarters in Dublin.

The cutbacks will allow Warner to focus on the U.S., where it's launching an osteoporosis remedy and an oral contraceptive, Hans van Zoonen, president of Warner's European and international operations, said in a statement. "The restructuring initiative will allow us to focus on growth opportunities that match Warner Chilcott's key competitive strengths, including the launches of Atelvia and Lo Loestrin Fe in the United States," said van Zoonen, who's also president of global marketing.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.